<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416089</url>
  </required_header>
  <id_info>
    <org_study_id>PR-14095</org_study_id>
    <nct_id>NCT02416089</nct_id>
  </id_info>
  <brief_title>Tampostat for Management of Postpartum Hemorrhage</brief_title>
  <official_title>Tampostat: A Low-cost, Self-regulating Tamponade for Management of Postpartum Hemorrhage in Bangladesh</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grand Challenges Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jibon Health Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaheed Suhrawardi Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dhaka Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Centre for Diarrhoeal Disease Research, Bangladesh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, feasibility and applicability of a new
      device 'Tampostat' in the management of primary postpartum hemorrhage and compare the
      efficacy of 'Tampostat' in terms of arresting primary PPH with that of the conventional
      condom catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 2-year study having two parts. Part A will be a Proof of Concept (POC) study
      that will be conducted at the Obstetrical Ward of Shaheed Suhrawardi Medical College Hospital
      (ShSMCH) and Dhaka Medical College Hospital (DMCH). There is no sample size estimation of
      this POC study that will assess safety, feasibility and applicability of using Tampostat on 5
      consenting women with PPH for each hospital. Part B of the study will be an open label,
      randomized clinical trial that will be conducted at the Obstetrical Ward of Dhaka Medical
      College Hospital (DMCH). In this part, 344 consenting women with primary PPH will be
      enrolled, and allocated to either Tampostat or the control intervention in equal numbers per
      randomization (172 patients in each arm). In both these parts, Tampostat will be used only
      when Active Management of Third Stage of Labour (AMTSL) has failed to prevent PPH within 24
      hours after delivery. All the doctors involved in the provision of care and treatment to PPH
      patients will be trained on the WHO's standard of care; they will also receive training on
      appropriate use of the devices to be used in this trial. An expert committee constituted of
      OBGYN professionals, clinical trial specialists, and statisticians will oversee the technical
      management of patients, data collection and their procedures, and ethical issues in this
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Tampostat as measured by number of serious adverse events in primary PPH management</measure>
    <time_frame>2 months</time_frame>
    <description>The safety of Tampostat [no. of Serious adverse events i.e. Incidence of air embolism, injury to the uterine wall, pain during inflation of condom &amp; continuation of vaginal /uterine bleeding during use of Tampostat] in primary PPH management.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Tampostat as measured by number of successful cases in arresting bleeding in Primary PPH</measure>
    <time_frame>12 months</time_frame>
    <description>Efficacy [number of successful cases in arresting bleeding due to primary PPH from atonic uterus] of Tampostat in the management of primary postpartum hemorrhage (PPH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the efficacy of Tampostat as measured by number of successful cases in arresting primary PPH and the time takes to arrest the bleeding with that of the condom catheter tamponade</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of the efficacy of Tampostat in terms of arresting primary PPH due to atonic uterus with that of the conventional condom catheter tamponade [no. of successful cases in arresting primary post partum bleeding using Tampostat and condom catheter and the time both takes to arrest the bleeding]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility as measured by number of physicians consider Tampostat as a feasible device in arresting primary PPH</measure>
    <time_frame>2 months</time_frame>
    <description>The feasibility of Tampostat[number of physicians consider Tampostat as a feasible device in arresting primary PPH due to atonic uterus] in the management of primary PPH by</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Applicability of Tampostat as measured by rating by service providers using pre established scoring system in the management of primary PPH</measure>
    <time_frame>2 months</time_frame>
    <description>Applicability[rating by service providers on applicability of the device using pre established scoring system]of Tampostat in the management of primary PPH due to atonic uterus.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Tampostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tampostat™ is a self-regulating, low cost, pressure based emergency obstetric device designed specifically for use in low-resource settings. It has 6 parts: probe, condom, O ring, nerve centre, tube and bulb pump. It offers significant benefits over the current model by simplifying the insertion process, reducing the need for constant monitoring, eliminating leakage and the need for sterile saline, and using a pressure-based mechanism to apply consistent pressure to all women regardless of uterus size.Women who develop PPH even after applying AMTSL at the hospital or women who visit the hospital with PPH within 24 hours after delivery will be managed by Tampostat for the intervention arm or by the condom catheter tamponade in the control arm(172 patients in each arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Condom catheter tamponade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Condom catheter tamponade have been used by medical professionals for several years in the management of atonic (primary) PPH. In this approach, Sterile rubber catheter fitted with a condom as a tamponade balloon device and using normal saline to inflate the condom.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tampostat</intervention_name>
    <arm_group_label>Tampostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Condom catheter tamponade</intervention_name>
    <arm_group_label>Condom catheter tamponade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women who delivered their baby at the site hospital, or attended the site hospital
             with PPH that started within the last 24 hours.

          2. Women with primary PPH have received AMTSL.

          3. PPH is due to atonic uterus.

          4. Provides written informed consent for enrolment in the study.

        Exclusion Criteria:

          1. Primary PPH caused by retained placenta or ruptured uterus.

          2. Women who delivered before 28 weeks of gestation.

          3. Women not willing to participate in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aminur Rahman, MBBS,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Centre for Diarrhoeal Disease Research, Bangladesh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aminur Rahman, MBBS,MSc</last_name>
    <phone>8801713257399</phone>
    <email>draminur@icddrb.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saima Sultana, MBBS,MPH</last_name>
    <phone>8801732131417</phone>
    <email>saima_sultana0013@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Obstetrical Ward of Shaheed Suhrawardi Medical College Hospital (ShSMCH) and Dhaka Medical College Hospital (DMCH)</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatema Ashraf, MBBS,FCPS</last_name>
      <phone>8801711855941</phone>
      <email>fatema_ashraf@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Ferdousi Islam Islam, MBBS,FCPS</last_name>
      <phone>8801711695557</phone>
      <email>obs_gynae_dmch@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Iqbal Anwar, Dr.PH, MPHM,MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikail Kamal, B.S. Biomedical Engineering</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>K Zaman, PhD ,MPH ,MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dewan Emdadul Hoque, MBBS,MPH,MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sadika Akter, MSS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ferdousi Islam, MBBS,FCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fatema Ashraf, MBBS,FCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aaron M. Kyle, Doctor of Philosophy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sayeba Akhter, MBBS,FCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aminur Rahman, MBBS,MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <reference>
    <citation>Condous GS, Arulkumaran S, Symonds I, Chapman R, Sinha A, Razvi K. The &quot;tamponade test&quot; in the management of massive postpartum hemorrhage. Obstet Gynecol. 2003 Apr;101(4):767-72.</citation>
    <PMID>12681884</PMID>
  </reference>
  <reference>
    <citation>Vitthala S, Tsoumpou I, Anjum ZK, Aziz NA. Use of Bakri balloon in post-partum haemorrhage: a series of 15 cases. Aust N Z J Obstet Gynaecol. 2009 Apr;49(2):191-4. doi: 10.1111/j.1479-828X.2009.00968.x.</citation>
    <PMID>19432609</PMID>
  </reference>
  <results_reference>
    <citation>Seligman, B. and X. Liu, Economic assessment of interventions for reducing postpartum hemorrhage in developing countries. 2006: Abt Associates.</citation>
  </results_reference>
  <results_reference>
    <citation>Organization, W.H., Make Every Mother and Child Count: The World Health Report. 2005: World Health Organization.</citation>
  </results_reference>
  <results_reference>
    <citation>Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006 Apr 1;367(9516):1066-74. Review.</citation>
    <PMID>16581405</PMID>
  </results_reference>
  <results_reference>
    <citation>National Institute of Population Research and Training (NIPORT), M.E., and icddr,b, Bangladesh Maternal Mortality and Health Care Survey 2010, M.E. NIPORT, and icddr,b, Editor. 2012: Dhaka.</citation>
  </results_reference>
  <results_reference>
    <citation>Lalonde A, Daviss BA, Acosta A, Herschderfer K. Postpartum hemorrhage today: ICM/FIGO initiative 2004-2006. Int J Gynaecol Obstet. 2006 Sep;94(3):243-53. Epub 2006 Jul 12.</citation>
    <PMID>16842791</PMID>
  </results_reference>
  <results_reference>
    <citation>Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labour. Cochrane Database Syst Rev. 2000;(3):CD000007. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD000007.</citation>
    <PMID>10908457</PMID>
  </results_reference>
  <results_reference>
    <citation>Abu-Heija AT, Jallad FF. Emergency peripartum hysterectomy at the Princess Badeea Teaching Hospital in north Jordan. J Obstet Gynaecol Res. 1999 Jun;25(3):193-5.</citation>
    <PMID>10467792</PMID>
  </results_reference>
  <results_reference>
    <citation>Bakri YN, Amri A, Abdul Jabbar F. Tamponade-balloon for obstetrical bleeding. Int J Gynaecol Obstet. 2001 Aug;74(2):139-42.</citation>
    <PMID>11502292</PMID>
  </results_reference>
  <results_reference>
    <citation>Doumouchtsis SK, Papageorghiou AT, Arulkumaran S. Systematic review of conservative management of postpartum hemorrhage: what to do when medical treatment fails. Obstet Gynecol Surv. 2007 Aug;62(8):540-7. Review.</citation>
    <PMID>17634155</PMID>
  </results_reference>
  <results_reference>
    <citation>Georgiou C. Balloon tamponade in the management of postpartum haemorrhage: a review. BJOG. 2009 May;116(6):748-57. doi: 10.1111/j.1471-0528.2009.02113.x. Review.</citation>
    <PMID>19432563</PMID>
  </results_reference>
  <results_reference>
    <citation>Seror J, Allouche C, Elhaik S. Use of Sengstaken-Blakemore tube in massive postpartum hemorrhage: a series of 17 cases. Acta Obstet Gynecol Scand. 2005 Jul;84(7):660-4.</citation>
    <PMID>15954876</PMID>
  </results_reference>
  <results_reference>
    <citation>Rather, S.Y., et al., Use of condom to control intractable PPH. JK science, 2010. 12(3)</citation>
  </results_reference>
  <results_reference>
    <citation>Rathore AM, Gupta S, Manaktala U, Gupta S, Dubey C, Khan M. Uterine tamponade using condom catheter balloon in the management of non-traumatic postpartum hemorrhage. J Obstet Gynaecol Res. 2012 Sep;38(9):1162-7. doi: 10.1111/j.1447-0756.2011.01843.x. Epub 2012 Apr 30.</citation>
    <PMID>22540529</PMID>
  </results_reference>
  <results_reference>
    <citation>Tindell K, Garfinkel R, Abu-Haydar E, Ahn R, Burke TF, Conn K, Eckardt M. Uterine balloon tamponade for the treatment of postpartum haemorrhage in resource-poor settings: a systematic review. BJOG. 2013 Jan;120(1):5-14. doi: 10.1111/j.1471-0528.2012.03454.x. Epub 2012 Aug 13. Review.</citation>
    <PMID>22882240</PMID>
  </results_reference>
  <results_reference>
    <citation>Georgiou C. Intraluminal pressure readings during the establishment of a positive 'tamponade test' in the management of postpartum haemorrhage. BJOG. 2010 Feb;117(3):295-303. doi: 10.1111/j.1471-0528.2009.02436.x. Epub 2009 Nov 26.</citation>
    <PMID>19943825</PMID>
  </results_reference>
  <results_reference>
    <citation>Mirski MA, Lele AV, Fitzsimmons L, Toung TJ. Diagnosis and treatment of vascular air embolism. Anesthesiology. 2007 Jan;106(1):164-77. Review.</citation>
    <PMID>17197859</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaikh N, Ummunisa F. Acute management of vascular air embolism. J Emerg Trauma Shock. 2009 Sep;2(3):180-5. doi: 10.4103/0974-2700.55330.</citation>
    <PMID>20009308</PMID>
  </results_reference>
  <results_reference>
    <citation>Akhter S, Begum MR, Kabir Z, Rashid M, Laila TR, Zabeen F. Use of a condom to control massive postpartum hemorrhage. MedGenMed. 2003 Sep 11;5(3):38.</citation>
    <PMID>14600674</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tampostat</keyword>
  <keyword>Tamponade</keyword>
  <keyword>Postpartum hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

